We report the results of a phase I study, Fred Hutchison Cancer Research Center (FHCRC) Protocol #1796, in ten patients with refractory, metastatic melanoma receiving autologous CD8+ T cell clones targeting a melanoma-associated antigen (MART-1, gp100, or tyrosinase), without and with prior fludarabine lymphodepletion. The gene discussed is CD8A; the disease is melanoma.